The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...

A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.

October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...

You can control where you focus your attention,” said Anne M. Reb, PhD, NP, who recently presented on a nurse-led ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

While pregnancy-associated cancer risks increased with age, breast cancer during pregnancy tended to not impact obstetric ...

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...

An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma. Ciltacabtagene autoleucel (cilta-cel; Carvykti) ...